{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Tiyaboonchai A"],"funding":["NIDDK NIH HHS","U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases"],"pagination":["7391"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9712609"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["13(1)"],"pubmed_abstract":["Expression of guide RNAs in the CRISPR/Cas9 system typically requires the use of RNA polymerase III promoters, which are not cell-type specific. Flanking the gRNA with self-cleaving ribozyme motifs to create a self-cleaving gRNA overcomes this limitation. Here, we use self-cleaving gRNAs to create drug-selectable gene editing events in specific hepatocyte loci. A recombinant Adeno Associated Virus vector targeting the Albumin locus with a promoterless self-cleaving gRNA to create drug resistance is linked in cis with the therapeutic transgene. Gene expression of both are dependent on homologous recombination into the target locus. In vivo drug selection for the precisely edited hepatocytes allows >30-fold expansion of gene-edited cells and results in therapeutic levels of a human Factor 9 transgene. Importantly, self-cleaving gRNA expression is also achieved after targeting weak hepatocyte genes. We conclude that self-cleaving gRNAs are a powerful system to enable cell-type specific in vivo drug resistance for therapeutic gene editing applications."],"journal":["Nature communications"],"pubmed_title":["Self-cleaving guide RNAs enable pharmacological selection of precise gene editing events in vivo."],"pmcid":["PMC9712609"],"funding_grant_id":["F32 DK117516","1 F2 DK117516-01"],"pubmed_authors":["Posey J","Pelz C","Grompe M","Tiyaboonchai A","Vonada A","Wakefield L"],"additional_accession":[]},"is_claimable":false,"name":"Self-cleaving guide RNAs enable pharmacological selection of precise gene editing events in vivo.","description":"Expression of guide RNAs in the CRISPR/Cas9 system typically requires the use of RNA polymerase III promoters, which are not cell-type specific. Flanking the gRNA with self-cleaving ribozyme motifs to create a self-cleaving gRNA overcomes this limitation. Here, we use self-cleaving gRNAs to create drug-selectable gene editing events in specific hepatocyte loci. A recombinant Adeno Associated Virus vector targeting the Albumin locus with a promoterless self-cleaving gRNA to create drug resistance is linked in cis with the therapeutic transgene. Gene expression of both are dependent on homologous recombination into the target locus. In vivo drug selection for the precisely edited hepatocytes allows >30-fold expansion of gene-edited cells and results in therapeutic levels of a human Factor 9 transgene. Importantly, self-cleaving gRNA expression is also achieved after targeting weak hepatocyte genes. We conclude that self-cleaving gRNAs are a powerful system to enable cell-type specific in vivo drug resistance for therapeutic gene editing applications.","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Nov","modification":"2025-04-19T03:36:55.755Z","creation":"2025-04-07T13:44:29.846Z"},"accession":"S-EPMC9712609","cross_references":{"pubmed":["36450762"],"doi":["10.1038/s41467-022-35097-5"]}}